Elsevier Announces the Anxiety and Depression: 21st Neuropharmacology Conference
Oxford, 9 March 2011 - Elsevier, the leading publisher of scientific, technical and medical information products and services, today announced that the Anxiety and Depression: 21st Neuropharmacology Annual Conference will take place in Virginia, USA on 10-11 November 2011 as a satellite to the 2011 Meeting of the Society for Neuroscience.
Anxiety and depression are amongst the most common brain disorders, with significant consequences for the individual and society. The 21st Neuropharmacology annual conference will bring together the leading experts in the field of psychiatry, neuroscience and pharmacology to present and discuss the latest research.
The scientific committee composed of acknowledged opinion leaders in anxiety and depression from across the spectrum of research areas will work alongside organizers from Elsevier to develop a multidisciplinary programme.
“The 21st Neuropharmacology Conference on Anxiety and Depression provides researchers with a marvelous opportunity to share knowledge and network with their peers,” said Michael Osuch, executive publisher at Elsevier.
Among the topics covered at the Anxiety and Depression Conference are:
• Emerging Therapeutic Targets in Depression
• Emerging Therapeutic Targets in Anxiety
• Animal Models
• Genetics and Epigenetics in Depression and Anxiety
• Imaging
• Developmental Aspects of Anxiety and Depression
• Neuronal Circuits Underlying Anxiety and Depression
• Fear Extinction
• Mechanism of Action of Antidepressants and Anxiolytics
Attendees are welcome to register at 
www.neuropharmacology-conference.elsevier.com
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Francesca Webb
+44 (0) 1865 843244
f.webb@elsevier.com
